Domperidone
- TRADE NAMES: Evoxin; Motilium (Johnson & Johnson)
- INDICATIONS: Investigational antiemetic, gastroesophageal reflux disease (GERD), nausea, vomiting
- CLASS: Antiemetic, Dopamine receptor antagonist
- HALF-LIFE: 7–8 hours
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Bromocriptine, Darifenacin, Hydromorphone, Ketoconazole, Meptazinol, Oxybutynin, Tiotropium, Trospium
PREGNANCY CATEGORY: N/A
Please login to see the rest of this drug profile
SKIN.
MUCOSAL.
CARDIOVASCULAR.
CENTRAL NERVOUS SYSTEM.
ENDOCRINE/METABOLIC.
GASTROINTESTINAL/HEPATIC.
NEUROMUSCULAR/SKELETAL.
OTHER.
Click on the DRUG REVIEW ARTICLE tab (above) to see a review of domperidone in the Taylor & Francis journal Expert Opinion on Drug Safety. (Note that non-subscribers to the journal will only be able to see an abstract of the article.)
Page last updated 08/01/2022
Symbol key
Incidence 
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Seriousness
- Hospitalization possible
- Life threatening
- Fatal
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric
